Stopping GLP-1 drugs could increase heart attack risk for some, study says

A new study suggests that patients with type 2 diabetes who stop taking GLP-1 weight loss medications may face a doubled risk of heart attack, stroke, or death. Researchers caution that the study is observational and cannot definitively prove that stopping the drug is the direct cause of these health events.
Why it matters
As GLP-1 drugs become widely used for weight loss and diabetes, understanding the risks of discontinuation is critical for patient safety and medical guidance.
Stopping treatment of type 2 diabetes with GLP-1 weight loss medications may lead to a doubled risk of heart attack, stroke or death, a new study shows.
The study, published Monday in the Lancet Regional Health Europe, looked at more than 80,000 Italians with type 2 diabetes and no established heart disease. Data was collected between 2004 and 2024.
Researchers found four in every 100 of those people a year who stopped taking GLP-1 treatments had a non-fatal heart attack or stroke, or died, compared to about two in 100 of the people who stayed on the medication.
Those with a body mass index of 30 or more, people considered medically obese, also showed a higher risk among those who stopped treatment than those under that BMI range.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in